The Demise of Chemotherapy in Front-Line mCRPC?
15 Feb 2013, by Neesha Suvarna
Oncology Conference Insight - ASCO GU 2013 ---
The metastatic castrate-resistant prostate cancer (mCRPC) market appears to be on a trajectory toward a relinquishment to novel hormonal agents and a regression of chemotherapy and other targeted therapies to later lines. If Jevtana manages to supersede docetaxel, it may only be a marginal improvement in this field, with a swap of one taxane for another. MORE